União Europeia - maltês - EMA (European Medicines Agency)

intervet international bv - razez tal-virus tal-influwenza ekwina: a / equine-2 / afrika t'isfel / 4/03, a / equine-2 / newmarket / 2/93, toxoid tat-tetnu - virus tal-influwenza ekwina + clostridium - Żwiemel - immunizzazzjoni attiva ta 'żwiemel minn sitt xhur ta' età kontra l-influwenza taż-żwiemel biex tnaqqas is-sinjali kliniċi u l-eskrezzjoni tal-virus wara l-infezzjoni, u immunizzazzjoni attiva kontra t-tetnu biex tevita l-mortalità.

União Europeia - maltês - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - clostridium tetani toxoid / kvp 2242 virus / vcp1529 virus / għal vcp1533 għal virus / vcp3011 virus - immunologicals for equidae, live viral and inactivated bacterial vaccines, equine influenza virus + clostridium - Żwiemel - immunizzazzjoni attiva ta 'żwiemel ta' erba 'xhur jew akbar kontra l-influwenza taż-żwiemel biex jitnaqqsu s-sinjali kliniċi u l-eskrezzjoni tal-virus wara infezzjoni, u kontra t-tetnu biex tiġi evitata l-mortalità.

União Europeia - maltês - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - Ħnieżer - vaċċini - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 u 4. l-użu ta dengvaxia għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.

União Europeia - maltês - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - sklerosi multipla - immunosuppressanti selettivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 u 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

União Europeia - maltês - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosoppressanti - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 u 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

União Europeia - maltês - EMA (European Medicines Agency)

intervet international bv - razez tal-virus ta 'l-influwenza taż-żwiemel: a / equine-2 / afrika t'isfel / 4/03, a / equine-2 / newmarket / 2/93 - virus tal-influwenza ekwina - Żwiemel - immunizzazzjoni attiva ta 'żwiemel minn sitt xhur ta' età kontra l-influwenza taż-żwiemel biex jitnaqqsu s-sinjali kliniċi u l-eskrezzjoni tal-virus wara l-infezzjoni.

União Europeia - maltês - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - rituximab - lymphoma, non-hodgkin; microscopic polyangiitis; leukemia, lymphocytic, chronic, b-cell; wegener granulomatosis - aġenti antineoplastiċi - rituzena huwa indikat fl-adulti għall-indikazzjonijiet li ġejjin:mhux ta 'hodgkin (nhl)rituzena huwa indikat għall-kura ta' pazjenti mhux trattati qabel ma l-istadju iii-iv limfoma follikulari flimkien mal-kimoterapija. rituzena monoterapija hija indikata għat-trattament ta 'pazjenti b'stadju iii-iv limfoma follikulari li huma kemo reżistenti jew li qegħdin fit-tieni jew aktar episodju ta' rkadar wara kimoterapija. rituzena huwa indikat għall-kura ta 'pazjenti bil-tixrid pożittiv cd20 taċ-ċelluli b kbar mhux ta' hodgkin il-limfoma f'kombinazzjoni ma ' chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) l-kimoterapija. lewkimja limfoċitika kronika (cll)rituzena flimkien ma 'kimoterapija huwa indikat għat-trattament ta' pazjenti li ma kienux trattati qabel u li reġgħet tfaċċat/refrattarja cll. hemm biss informazzjoni limitata disponibbli fuq l-effikaċja u s-sigurtà għall-pazjenti li qabel kienu kkurati b'antikorpi monoklonali inkluż rituzenaor pazjenti refrattarji għal preċedenti rituzena flimkien ma ' kimoterapija. granulomatosi b'polianġite u mikroskopika polyangiitisrituzena, flimkien ma 'glukokortikosterojdi, huwa indikat għall-induzzjoni ta' remissjoni f'pazjenti adulti b'mard sever, attiv granulomatosi b'polianġite (wegener) (fap) u polianġite mikroskopika (mpa).

União Europeia - maltês - EMA (European Medicines Agency)

merck sharp & dohme b.v. - vaċċin tal-papillomavirus uman [tipi 6, 11, 16, 18, 31, 33, 45, 52, 58] (rikombinanti, assorbjati) - condylomata acuminata; papillomavirus infections; immunization; uterine cervical dysplasia - vaċċini għal papillomavirus - gardasil 9 huwa indikat għall-immunizzazzjoni attiva ta 'l-individwi mill-età ta'9 snin kontra l-hpv-mard:premalignant leżjonijiet u l-kanċer li jaffettwa l-ċerviċi, vulva, tal-vaġina u l-anus ikkawżat minn hpv ta' vaċċin typesgenital-felul (kondiloma acuminata) ikkawżata mill-speċifiċi tipi ta ' hpv. ara t-taqsimiet 4. 4 u 5. 1 għal tagħrif importanti dwar l-informazzjoni li ssostni dawn l-indikazzjonijiet. l-użu ta ' gardasil 9 għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.

União Europeia - maltês - EMA (European Medicines Agency)

merck sharp & dohme b.v. - rotavirus serotip g1, serotip g2, serotip g3, serotip g4, serotip p1 - immunization; rotavirus infections - vaccines, viral vaccines - rotateq huwa indikat għall-immunizzazzjoni attiva tat-trabi mill-età ta 'sitt ġimgħat sa 32 ġimgħa għall-prevenzjoni ta' gastroenterite minħabba infezzjoni ta 'rotavirus. rotateq għandu jintuża fuq il-bażi ta ' rakkomandazzjonijiet uffiċjali.

União Europeia - maltês - EMA (European Medicines Agency)

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - herpes zoster - vaċċini - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. l-użu ta shingrix għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.